Fig. 3

Survival in patients treated with pembrolizumab. Kaplan–Meier estimates of a progression-free survival per RECIST v1.1 by central imaging vendor review and b overall survival (all-patients-as-treated population). RECIST Response Evaluation Criteria in Solid Tumors